Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Tyzeka vs Hepsera



Part 1 (24 weeks)
Mean log reduction in viral load
was 6.30 for Tyzeka vs 4.97 for Hepsera;
% of patients PCR-negative was
39% for Tyzeka vs 12% for Hepsera.



Part 2 (52 weeks)
At 24 weeks, half of the Hepsera patients in
the trial were switched to Tyzeka and thus
there were three arms: Tyzeka for 52 weeks,
Hepsera for 52 weeks, and the switch arm
consisting of Hepsera for 24 weeks followed
by Tyzeka fro 28 weeks.

The chart shows the % of patients in each
arm with undetectable virus by PCR.